Carregant...
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD), or are in advanced...
Guardat en:
| Publicat a: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams & Wilkins
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8063619/ https://ncbi.nlm.nih.gov/pubmed/33406479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000918 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|